Preliminary trials have demonstrated a role of IGF-1 intratympanic injections for the treatment of refractory sensorineural hearing loss (although this has not been studied in patients whose hearing loss is related to teprotumumab) (23). Here, IGF1 is linked to hearing loss disorder.